Regulators of G protein signaling 12 promotes osteoclastogenesis in bone remodeling and pathological bone loss

Cell Death and Differentiation

Volumn 22, Issue 12, 2015, Pages 2046-2057

  Yuan, X ^a   Cao, J ^b   Liu, T ^a   Li, Y P ^c   Scannapieco, F ^a   He, X ^d   Oursler, M J ^e   Zhang, X ^f   Vacher, J ^g   Li, C ^a   Olson, D ^a   Yang, S ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b GRAND FORKS HUMAN NUTRITION RESEARCH CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

^d CHINA MEDICAL UNIVERSITY   (China)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; RGS PROTEIN; RGS12 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT2; UNCLASSIFIED DRUG; CALCIUM; CD11B ANTIGEN; LIPOPOLYSACCHARIDE; NFATC1 PROTEIN, MOUSE; RGS12 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE DISEASE; BONE MASS; BONE REMODELING; CALCIUM SIGNALING; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; HEMATOPOIETIC CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRABECULAR BONE; ANIMAL; BONE; BONE DEVELOPMENT; BONE MARROW CELL; CELL CULTURE; CYTOLOGY; DEFICIENCY; DIAGNOSTIC IMAGING; DRUG EFFECTS; FEMUR; GENETICS; HEMATOPOIETIC STEM CELL; KNOCKOUT MOUSE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; OSTEOCLAST; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD11B; BONE AND BONES; BONE MARROW CELLS; BONE REMODELING; CALCIUM; CELL DIFFERENTIATION; CELLS, CULTURED; FEMUR; HEMATOPOIETIC STEM CELLS; LIPOPOLYSACCHARIDES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOGENESIS; RGS PROTEINS; X-RAY MICROTOMOGRAPHY;

EID: 84947019222     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.45     Document Type: Article

References (61)

1. Zaidi M. Skeletal remodeling in health and disease. Nat Med 2007; 13: 791-801.
2. Kawai M, Modder UI, Khosla S, Rosen CJ. Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov 2011; 10: 141-156.
3. Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol 2011; 7: 700-707.
4. Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo) 2013; 2013: 125705.
5. Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res 2013; 28: 711-722.
6. Boyce BF, Rosenberg E, de Papp AE, Duong le T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur J Clin Invest 2012; 42: 1332-1341.
7. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
8. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998; 253: 395-400.
9. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96: 3540-3545.
10. Martin TJ. Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop 2013; 4: 186-197.
11. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007; 40: 251-264.
12. Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett 2009; 583: 2435-2440.
13. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901.
14. 2+ signaling during osteoclast differentiation. IBMS Bonekey 2009; 6: 301-306.
15. Snow BE, Antonio L, Suggs S, Gutstein HB, Siderovski DP. Molecular cloning and expression analysis of rat Rgs12 and Rgs14. Biochem Biophys Res Commun 1997; 233: 770-777.
16. Schiff ML, Siderovski DP, Jordan JD, Brothers G, Snow B, De Vries L et al. Tyrosine-kinasedependent recruitment of RGS12 to the N-type calcium channel. Nature 2000; 408: 723-727.
17. Snow BE, Brothers GM, Siderovski DP. Molecular cloning of regulators of G-protein signaling family members and characterization of binding specificity of RGS12 PDZ domain. Methods Enzymol 2002; 344: 740-761.
18. Sambi BS, Hains MD, Waters CM, Connell MC, Willard FS, Kimple AJ et al. The effect of RGS12 on PDGFbeta receptor signalling to p42/p44 mitogen activated protein kinase in mammalian cells. Cell Signal 2006; 18: 971-981.
19. Snow BE, Hall RA, Krumins AM, Brothers GM, Bouchard D, Brothers CA et al. GTPase activating specificity of RGS12 and binding specificity of an alternatively spliced PDZ (PSD-95/Dlg/ZO-1) domain. J Biol Chem 1998; 273: 17749-17755.
20. Willard MD, Willard FS, Li X, Cappell SD, Snider WD, Siderovski DP. Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor-mediated differentiation. EMBO J 2007; 26: 2029-2040.
21. Yang S, Li YP. RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts in vitro. J Bone Miner Res 2007; 22: 45-54.
22. Ferron M, Vacher J. Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice. Genesis 2005; 41: 138-145.
23. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995; 269: 1427-1429.
24. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008; 118: 3775.
25. Yang S, Li YP, Liu T, He X, Yuan X, Li C et al. Mx1-Cre mediated Rgs12 conditional knockout mice exhibit increased bone mass phenotype. Genesis 2013; 51: 201-209.
26. Suda T, Jimi E, Nakamura I, Takahashi N. Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol 1997; 282: 223-235.
27. Bradley EW, Oursler MJ. Osteoclast culture and resorption assays. Osteoporosis. Springer: New York City, 2008, pp 19-35.
28. Marchisio PC, Cirillo D, Naldini L, Primavera MV, Teti A, Zambonin-Zallone A. Cell-substratum interaction of cultured avian osteoclasts is mediated by specific adhesion structures. J Cell Biol 1984; 99: 1696-1705.
29. Wilson SR, Peters C, Saftig P, Bromme D. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 2009; 284: 2584-2592.
30. Zeng W, Xu X, Popov S, Mukhopadhyay S, Chidiac P, Swistok J et al. The N-terminal domain of RGS4 confers receptor-selective inhibition of G protein signaling. J Biol Chem 1998; 273: 34687-34690.
31. Taylor CW, Thorn P. Calcium signalling: IP3 rises again...and again. Curr Biol 2001; 11: R352-R355.
32. Ishii M, Kurachi Y. Physiological actions of regulators of G-protein signaling (RGS) proteins. Life Sci 2003; 74: 163-171.
33. 2+/calmodulin competitively bind to the regulators of G-protein-signalling (RGS) domain of RGS4 and reciprocally regulate its action. Biochem J 2005; 385: 65-73.
34. Li L, Khansari A, Shapira L, Graves DT, Amar S. Contribution of interleukin-11 and prostaglandin(s) in lipopolysaccharide-induced bone resorption in vivo. Infect Immun 2002; 70: 3915-3922.
35. Ohishi M, Matsumura Y, Aki D, Mashima R, Taniguchi K, Kobayashi T et al. Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines. J Immunol 2005; 174: 3024-3031.
36. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002; 416: 744-749.
37. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408: 600-605.
38. Beamer WG, Shultz KL, Donahue LR, Churchill GA, Sen S, Wergedal JR et al. Quantitative trait loci for femoral and lumbar vertebral bone mineral density in C57BL/6 J and C3H/HeJ inbred strains of mice. J Bone Miner Res 2001; 16: 1195-1206.
39. Miles RR, Sluka JP, Santerre RF, Hale LV, Bloem L, Boguslawski G et al. Dynamic regulation of RGS2 in bone: potential new insights into parathyroid hormone signaling mechanisms. Endocrinology 2000; 141: 28-36.
40. 2+]i oscillation regulation. Genes Dev 2007; 21: 1803-1816.
41. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Ruegg C, Christofori G. Myeloid cells contribute to tumor lymphangiogenesis. PLoS One 2009; 4: e7067.
42. Hollinger S, Hepler JR. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 2002; 54: 527-559.
43. Aeschlimann D, Evans B. The vital osteoclast: how is it regulated? Cell Death Differ 2004; 11: S5-S7.
44. Chiang CY, Kyritsis G, Graves DT, Amar S. Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infect Immun 1999; 67: 4231-4236.
45. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000; 165: 618-622.
46. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B. Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun 1996; 64: 2371-2380.
47. Liu J,Wang S, Zhang P, Said-Al-Naief N, Michalek SM, Feng X. Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis. J Biol Chem 2009; 284: 12512-12523.
48. Society NAM. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause (New York) 2006; 13: 340.
49. Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 1991; 15: 175-191.
50. Park D, Spencer JA, Koh BI, Kobayashi T, Fujisaki J, Clemens TL et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell 2012; 10: 259-272.
51. Bensamoun SF, Hawse JR, Subramaniam M, Ilharreborde B, Bassillais A, Benhamou CL et al. TGFbeta inducible early gene-1 knockout mice display defects in bone strength and microarchitecture. Bone 2006; 39: 1244-1251.
52. Hawse JR, Iwaniec UT, Bensamoun SF, Monroe DG, Peters KD, Ilharreborde B et al. TIEG-null mice display an osteopenic gender-specific phenotype. Bone 2008; 42: 1025-1031.
53. Wang Y, Liu W, Masuyama R, Fukuyama R, Ito M, Zhang Q et al. Pyruvate dehydrogenase kinase 4 induces bone loss at unloading by promoting osteoclastogenesis. Bone 2012; 50: 409-419.
54. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999; 190: 1741-1754.
55. Monticelli S, Rao A. NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription. Eur J Immunol 2002; 32: 2971-2978.
56. Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factorrelated activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 2005; 280: 35209-35216.
57. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 2008; 22: 176-185.
58. Lakkakorpi PT, Horton MA, Helfrich MH, Karhukorpi EK, Vaananen HK. Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to the bone surface. J Cell Biol 1991; 115: 1179-1186.
59. Tamura T, Takahashi N, Akatsu T, Sasaki T, Udagawa N, Tanaka S et al. New resorption assay with mouse osteoclast-like multinucleated cells formed in vitro. J Bone Miner Res 1993; 8: 953-960.
60. Lai CF, Cheng SL, Mbalaviele G, Donsante C, Watkins M, Radice GL et al. Accentuated ovariectomy-induced bone loss and altered osteogenesis in heterozygous N-cadherin null mice. J Bone Miner Res 2006; 21: 1897-1906.
61. Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest 2012; 122: 3579.